CHU Lille, Université de Lille, Inserm U1011 - EGID, Institut Pasteur de Lille, Lille, France; CHU Lille, Institut Coeur Poumon, Cardiology, Lille, France.
CHU Lille, Université de Lille, Inserm U1011 - EGID, Institut Pasteur de Lille, Lille, France; CHU Lille, Hematology and Transfusion, Lille, France.
J Am Coll Cardiol. 2019 Mar 12;73(9):1078-1088. doi: 10.1016/j.jacc.2018.12.045.
For decades, numerous observations have shown an intimate relationship between von Willebrand factor (VWF) multimer profile and heart valve diseases (HVD). The current knowledge of the unique biophysical properties of VWF helps us to understand the longstanding observations concerning the bleeding complications in patients with severe HVD. Not only does the analysis of the VWF multimer profile provide an excellent evaluation of HVD severity, it is also a strong predictor of clinical events. Also of importance, VWF responds within minutes to any significant change in hemodynamic valve status, making it an accurate marker of the quality of surgical and transcatheter therapeutic interventions. The authors provide in this review a practical, comprehensive, and evidence-based framework of the concept of VWF as a biomarker in HVD, advocating for its implementation into the clinical decision-making process besides usual clinical and imaging evaluation. They also delineate critical knowledge gaps and research priorities to definitely validate this concept.
数十年来,众多观察结果表明,血管性血友病因子 (VWF) 多聚体谱与心脏瓣膜疾病 (HVD) 之间存在密切关系。目前对 VWF 独特的生物物理特性的了解有助于我们理解关于严重 HVD 患者出血并发症的长期观察结果。VWF 多聚体谱的分析不仅提供了对 HVD 严重程度的极好评估,也是临床事件的有力预测因子。同样重要的是,VWF 会在几分钟内对任何明显的血流动力学瓣膜状态变化作出反应,使其成为手术和经导管治疗干预质量的准确标志物。作者在这篇综述中提供了一个实用、全面和基于证据的 VWF 作为 HVD 生物标志物的概念框架,主张除了通常的临床和影像学评估外,将其纳入临床决策过程。他们还描绘了关键的知识空白和研究重点,以明确验证这一概念。